Semler Scientific (SMLR) Registration Filing summary

Company overview and business model

• Provides technology solutions to improve clinical effectiveness and efficiency for healthcare providers, with a focus on chronic disease evaluation and treatment.

• Main product, QuantaFlo, is FDA-cleared for diagnosing peripheral arterial disease (PAD) and is seeking expanded FDA clearance for broader cardiovascular indications.

• Recently adopted bitcoin as its primary treasury reserve asset, holding 828 bitcoins as of June 6, 2024, acquired for $57 million.

• Believes bitcoin is a reliable store of value and a potential inflation hedge, with no plans to purchase other cryptocurrencies.

Financial performance and metrics

• Stock price has experienced significant volatility, ranging from $21.03 to $51.54 per share in 2024.

• Volatility attributed to lower-than-expected Q1 2024 revenues and net profits, and the announcement of the bitcoin strategy.

• As of March 31, 2024, 6,919,771 shares were outstanding, with additional shares available under stock options and equity plans.

Use of proceeds and capital allocation

• Net proceeds from securities offerings will be used for general corporate purposes, including working capital, R&D, capital expenditures, potential acquisitions, and notably, the acquisition of additional bitcoin.

• Management retains broad discretion over allocation of proceeds.